Telomir Pharmaceuticals, Inc. 8-K

What Happened

• Telomir Pharmaceuticals (TELO) filed an 8-K reporting that Alan Weichselbaum is no longer serving as the Company’s Chief Financial Officer effective June 6, 2026. The board appointed Andriy Mushak as the Company’s fractional Chief Financial Officer; the appointment was made on June 3, 2026 and became effective June 6, 2026.
• Mr. Mushak, a 43-year-old Certified Public Accountant licensed in Massachusetts, currently is a Partner at LMAM Consulting Group, LLC and will provide services to Telomir under a consulting agreement with LMAM.

Key Details

• Effective date: June 6, 2026 (departure of prior CFO and start of Mushak’s role).
• Compensation: Telomir will pay Mr. Mushak $6,000 per month for the services provided under the consulting agreement with LMAM.
• Background: Mushak has 20+ years of SEC reporting, accounting compliance, and audit experience; previously served over a decade in Baker Tilly US, LLP’s audit practice and co-founded LMAM in 2025.
• Disclosures: The filing states Mr. Weichselbaum’s departure was not due to any disagreement with the Company. No family relationships or reportable related-party transactions involving Mr. Mushak were disclosed. A consulting agreement with LMAM was filed as an exhibit.

Why It Matters

• This is a material change in the company’s finance leadership and affects who oversees SEC reporting and financial statements; Telomir is using an experienced external CPA via a consulting arrangement rather than hiring an internal full-time CFO.
• The monthly fee ($6,000) and the consulting structure are concrete, short-term facts investors can use to assess continuity and cost of financial management while monitoring for any further changes to permanent finance leadership.